Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elismetrep - Mitsubishi Tanabe Pharma

Drug Profile

Elismetrep - Mitsubishi Tanabe Pharma

Alternative Names: MT 8554

Latest Information Update: 14 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Benzoic acids; Cyclopropanes; Isoquinolines; Neuroprotectants; Small molecules; Sulfonamides
  • Mechanism of Action TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Vasomotor symptoms
  • No development reported Neurological disorders

Most Recent Events

  • 15 Nov 2019 Mitsubishi Tanabe Pharma Development America completes a phase II trial in long-term extension study for Vasomotor symptoms in USA (PO) (NCT03541200)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Vasomotor-symptoms in Germany (PO)
  • 22 Nov 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top